LabCorp Acquires BioReference Assets from OPKO Health for $722 Million
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
LabCorp announced the acquisition of BioReference assets from OPKO Health. The transaction involves LabCorp paying approximately $722 million in cash, with total consideration potentially reaching $872 million. The acquired assets include BioReference specialty testing businesses, such as women’s-health services and the 4Kscore blood test.
From themarketsdaily.com
Why it matters
The divestiture allows OPKO Health to strategically refocus on its biopharmaceutical operations. The cash infusion from the transaction could strengthen OPKO Health’s balance sheet and support its drug-development programs. LabCorp expects the acquisition to expand access to laboratory services.
From themarketsdaily.com
Who's involved
- LabCorpAcquiring BioReference specialty testing businesses from OPKO Health.
- OPKO Health (Ireland)Selling BioReference assets to LabCorp.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Norges BankSpeculative
May see its investment value affected by the acquisition strengthening LabCorp's balance sheet and strategic position.